… Patients with exon 19 deletions had significant overall survival (OS) benefit under TKI treatment
(HR: 0.72, 95% CI: 0.60–0.88). Subgroup analyses showed that irreversible TKIs, but not …

… affected overall survival. The exposure rates for all epidermal growth factor receptor-tyrosine …
Overall 56.1% of patients were administered gefitinib as first-line therapy, and 39.0% were …

… EGFR-TKI to the first documentation of PD. Overall survival (OS) was calculated from first dose
of EGFR… The Kaplan-Meier method was used to estimate survival curves. The log-rank test …

… associated with EGFR. … EGFR–tyrosine kinase inhibitors (TKIs) on PFS and OS while
examining for heterogeneity of treatment effects between groups of patients with and without EGFR …

… In advanced non–small cell lung cancer (NSCLC) with activating mutations of the epidermal
growth factor receptor (EGFR) gene, EGFR tyrosine kinase inhibitor (EGFR-TKI) is the …

… of the epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) … EGFR
mutation-positive advanced non-small-cell lung cancer (NSCLC). Findings from final overall survival …

… The use of upfront epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) …
WBRT on overall survival (OS). After screening 1384 patients, a total of 141 EGFR-mutated …

… (EGFR) that are sensitive to tyrosine kinase inhibitors (TKIs) (exon 19 deletions or L858R
point mutations), guidelines recommend treatment with an EGFR-… as the preferred EGFR-TKI …

… A major focus of the study was overall survival, defined as the duration of … overall survival
rate more than localized treatment alone. Further, median survival time in our EGFR tyrosine …

… response to first-line EGFR-TKIs in patients with advanced NSCLC (34). Overall survival (OS)
is … investigated PFS as the clinical outcome, while overall survival (OS) was not explored. …